Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines

Jpn J Cancer Res. 2002 May;93(5):559-66. doi: 10.1111/j.1349-7006.2002.tb01291.x.

Abstract

Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in metastatic breast cancer. We compared the potential of various schedules of GAT to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. The extent of apoptotic induction was analyzed by flow cytometry with 7-aminoactinomycin D (7AAD) staining. Differences between various schedules in terms of apoptotic induction were statistically significant (P < 0.05). The most effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h followed by Pac + Gem. Schedules employing a 16-h interval between drug administrations induced higher levels of apoptosis in human breast cancer cell lines compared with schedules using a 4-h interval. The therapeutic efficacy of the experimental results shown in this paper has been clinically corroborated in a phase II trial in metastatic breast cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Apoptosis*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Cell Division
  • Cell Survival
  • Clinical Trials as Topic
  • Dactinomycin / pharmacology
  • Deoxycytidine / administration & dosage*
  • Deoxycytidine / analogs & derivatives*
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage*
  • Flow Cytometry
  • Gemcitabine
  • Humans
  • Paclitaxel / administration & dosage*
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Antibiotics, Antineoplastic
  • Deoxycytidine
  • Dactinomycin
  • Doxorubicin
  • Paclitaxel
  • Gemcitabine